GASTROENTEROLOGY ENROLLMENT FORM

	BAPTIST	DATE: DATE NEEDED:	SHIP TO: □ PATIENT □ O	FFICE		
	Ī			<u> </u>	DOP	
PATIENT INFO	ADDRESS					
ADDRESSCITYST HOME TELEPHONE MOBILE PHONE SS#						
Δ.	PLEASE FAX COPY OF IN	SURANCE CARD (FRONT & BAC	CK)	PRESCR	IPTION INFORM	ATION
	Diagnosis Codes		Cimzia® (Crohn's)	Hu	ımira® (Crohn's - UC)	Simponi® (UC)
	ate of Diagnosis:		□ <u>Starter Dose:</u>	Пс	ohn's/Ulcerative Colitis	☐ SmartJect Autoinjector
	K50.00 Crohn's Disease		Starter Kit	C+-	arter Kit	(100mg/ml)
	K51.80 Ulcerative Coliti		(200mg Pre-filled Syringe)	I 🗀 III uu	<u>iction Dose:</u>	☐ Prefilled Syringe (100mg/ml)
	□ 0ther:		☐ Vial (200mg/ml) & supplies ☐ Starter Directions:		ect 160mg (4 pens) SC on	□ Initial Dosing:
			□ Inject 400mg SC at		, then 80mg Kit(2 pens) on 5, then maintenance dosing	☐ Inject 200mg(2 autoinj/syringes SC on week 0, then 100mg (1
II.	reatment History		weeks 0, 2, and 4	1 '	3	
	New to this medicine Con	tinued Treatment	□ Other:		r:	100mg (1 autoinj/syringe) every
	continuing treatment, has pati		QTY: □1 pre-fill syr KIT		□1 KIT Refilis	4 weeks
	r stabilizeď? □ Yes □ No '	'	(6x200mg syr) ☐ 6 vials ☐ Refills		ntenance Dose:	☐ Maintenance Dosing:
P	atient Weight:kg / lb		O VIdIS L. Relilis_	I .	n (40mg/0.8ml)	☐ Inject 100mg (1 pen/syringe)
III A	llergies? ☐ Latex ☐ Other:		□ <u>Maintenance Dose:</u>	l Dro	mg/0.8ml efilled Syringe (PFS)	SC every 4 weeks
_	oncomitant Medications:		☐ Pre-filled Syringe (200mg/	'MI) □ Mair	ntenance Directions:	QTY: □ 3 autoing/syr on first
_	rohn's/UC Severity: Moderate		□ Vial (200mg/ml) & supplies	s 1 —	n: Inject 40mg (one pen)	dispense, and 1 for refills
	•	ctovaginal Fistulas? □Yes □No	☐ <u>Maintenance Directions:</u>	SC	every other week	□1 autoinj/syr
M	as patient been diagnosed with	-	Linject 400mg 3c every 4 we		S: Inject 40mg (one syringe)	□ Refills
11			Other:	SC	every other week	Other
22	as patient been diagnosed with	, ·	QTY: □2 pre-filled syr □4			
123	oes patient have serious/active		□ Refills	QTY: 🗆	2 □ Refills	Drug Name:
_	TB/PPD Test Results? ☐ No ☐ Yes ☐ Result?		Entyvio® (Crohn's/UC)	Re	micade® (Crohn's/UC)	
		ifection? ☐ Yes ☐ No - If Yes,	□ 300mg/20ml Vial	□Via	l (100mg/20ml)	☐ Strength:
	as Hepatitis B been ruled out or t		□ <u>Initial Directions:</u>		al Dosing:	□ Directions:
24	□ Other:		☐ Administer 300mg via IV infusion at Weeks 0, 2, and 6,	then Ad	minister 5 mg/kg	
	Prior Failed Medication(s) Medication		maintenance dosing.	(5)	ose =mg) 0, 2, & 6 weeks,	
١			□ Other:		en q 8 weeks	
			☐ Maintenance Directions:			QTY: - Refills
_			☐ Administer 300mg via IV		ntenance Dosing: minister ma/ka	
			infusion every 8 weeks.	every	ministermg/kg	
			□ Other:	□0th	ner:	
	.ength of Treatment Reason for Discontinuing		QTY: vials Refills_	QTY: [Vials Refills	
_			Supportive Care			
_	Medication		Methotrexate		Other	
	ength of Treatment		□ 2.5 mg tablets □ 25 r	mg/ml vials	Drug Name:	
	Reason for Discontinuing		□ Dosing:			
.		· · · · · · · · · · · · · · · · · · ·				
	Manufacturer's Support: Is poroduct manufacturer's spor					
	example: myHUMIRA, Access(QTY: 🗆 Refills_		QTY: 🗆 R	efills
IN	ECTION TRAINING P	atient has received injection train	ing Dhysisian Office to	nvovido inios	1	acy to provide injection training
IIV.		•				
<u>د</u> ک	Prescriber's Name:		Contact Person:			
IBER	Telephone: Fa		ex: Email: State: Zip:			
SCR	NIDI # ·	DEΔ # ·	Tay ID # •	CIT	.yModicaid Provis	state:
RES	NPI # : DEA # : Tax ID # : Medicaid Provider # :					
a Z	PRESCRIBER'S SIGNATURE (DATE) *IF BRAND DRUGS ARE PREFERRED, HANDWRITE "BRAND MEDICALLY NECESSARY" ABOVE					
L	authorize the Pharmacy noted above and its representatives to act as an agent to initiate and execute the insurance prior authorization process. ©Recept, IP All rights Reserved					

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.